Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136

European Journal of Cancer

Volumn 41, Issue 12, 2005, Pages 1811-1818

  Guichard, S M ^a   Macpherson, J S ^a   Thurston, D E ^b   Jodrell, D I ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

ABCB1; Colon cancer; DNA binding; Drug resistance; Interstrand cross linking agent; mdr 1; Minor groove; Ovarian cancer; Pyrrolobenzodiazepine; SJG 136

Indexed keywords

BENZODIAZEPINE DERIVATIVE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; SJG 136; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; COLON CANCER; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG POTENCY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINONES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG COMBINATIONS; HUMANS; IMMUNOBLOTTING; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED C57BL; P-GLYCOPROTEIN; PYRROLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSPLANTATION, HETEROLOGOUS; VERAPAMIL;

EID: 23644457140     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.04.026     Document Type: Article

References (20)

1. S.J. Gregson, P.W. Howard, and J.A. Hartley Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity J Med Chem 44 5 2001 737 748
2. J.A. Hartley, V.J. Spanswick, and N. Brooks SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity Cancer Res 64 18 2004 6693 6699
3. M.C. Alley, M.G. Hollingshead, and C.M. Pacula-Cox SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations Cancer Res 64 18 2004 6700 6706
4. C.J. Pepper, R.M. Hambly, and C.D. Fegan The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill Cancer Res 64 18 2004 6750 6755
5. S.V. Ambudkar, S. Dey, and C.A. Hrycyna Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu Rev Pharmacol Toxicol 39 1999 361 398
6. F. Thiebaut, T. Tsuruo, and H. Hamada Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues Proc Natl Acad Sci USA 84 21 1987 7735 7738
7. S. Hoffmeyer, O. Burk, and O. von Richter Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci USA 97 7 2000 3473 3478
8. K. Ueda, C. Cardarelli, and M.M. Gottesman Expression of a full-length cDNA for the human MDR-1 gene confers resistance to colchicine, doxorubicin, and vinblastine Proc Natl Acad Sci USA 84 9 1987 3004 3008
9. A.T. Fojo, K. Ueda, and D.J. Slamon Expression of a multidrug-resistance gene in human tumors and tissues Proc Natl Acad Sci USA 84 1 1987 265 269
10. U. Potocnik, M. Ravnik-Glavac, and R. Golouh Naturally occurring mutations and functional polymorphisms in multidrug resistance 1 gene: correlation with microsatellite instability and lymphoid infiltration in colorectal cancers J Med Genet 39 5 2002 340 346
11. Y. Tada, M. Wada, and T. Migita Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin Int J Cancer 98 4 2002 630 635
12. T. Yamada, A.S. Takaoka, and Y. Naishiro Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis Cancer Res 60 17 2000 4761 4766
13. P. Skehan, R. Storeng, and D. Scudiero New colorimetric cytotoxicity assay for anticancer-drug screening J Natl Cancer Inst 82 13 1990 1107 1112
14. P. Workman, P. Twentyman, and F. Balkwill United Kingdom Co-Ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia 2nd ed. Brit J Cancer 77 1998 1 10
15. M.C. Alley, M.G. Hollingshead, and C.M. Pacula-Cox Efficacy evaluations of SJG-136 (NSC 694501), a novel pyrrolobenzodiazepine dimer with broad spectrum antitumor activity Proc Am Assoc Cancer Res 43 2002
16. Y. Matsushima, F. Kanzawa, and A. Hoshi Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay Cancer Chemother Pharmacol 14 2 1985 104 107
17. C.O. Cardarelli, I. Aksentijevich, and I. Pastan Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters Cancer Res 55 5 1995 1086 1091
18. K.G. Louie, B.C. Behrens, and T.J. Kinsella Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine Cancer Res 45 5 1985 2110 2115
19. M.A. Barrand, T. Rhodes, and M.S. Center Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein Eur J Cancer 29A 3 1993 408 415
20. R.B. Kim, B.F. Leake, and E.F. Choo Identification of functionally variant MDR-1 alleles among European Americans and African Americans Clin Pharmacol Ther 70 2 2001 189 199